RBC Capital Defending Axsome Therapeutics (AXSM): 'we would be buyers at these levels'

October 14, 2026 5:58 AM

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $295.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found